The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s monoclonal antibodies (MAbS) market report forecasts the monoclonal antibodies (MAbS) market size to grow to $330.35 Billion by 2027, with a CAGR (compound annual growth rate) of 12%.

Learn More On The Monoclonal Antibodies (MAbS) Market Report 2023 – https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-global-market-report

Monoclonal Antibodies (MAbS) Market Size Forecast

The global monoclonal antibodies (MAbS) market is expected to grow from $188.18 billion in 2022 to $209.98 billion in 2023 at a compound annual growth rate (CAGR) of 11.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The monoclonal antibodies (mabs) market is expected to grow from $330.35 billion in 2027 at a CAGR of 12.0%.

North America held the largest monoclonal antibodies (MAbS) market share.

Key Monoclonal Antibodies (MAbS) Market Driver ­– Increase In The Prevalence Of Cost-Efficient Biosimilar Monoclonal Antibodies

The biosimilars’ aim is to curb the increasing cost of healthcare and handle economic pressure from the patient pod and governments to reduce the cost of medication and increase access to treatment. Biosimilars are pharmaceuticals that are developed to have similar properties to a biological drug that has already been approved. A biosimilar monoclonal antibody costs 20%–25% less than the original biologic drug. The number of clinical trials for a biosimilar is comparatively smaller than that of the original biologic drug, and this proves to be the reason for the low cost of a biosimilar drug. In India, a new biosimilar policy called the ‘Guidelines on Similar Biologics’ prepared by the Central Drugs Standard Control Organization (CSDCO) is expected to give a major boost to the Indian biosimilar drugs industry.

Request for A Sample Of The Global Monoclonal Antibodies (MAbS) Market Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2554&type=smp

Key Monoclonal Antibodies (MAbS) Market Trend – Witnessing Multiple Strategic Initiatives

The monoclonal antibody market has been witnessing multiple strategic initiatives in recent years. Top companies in the market are strategically acquiring start-ups and mid-sized companies to broaden their products and services. Strategic collaborations, acquisitions, and partnership agreements help vendors expand their existing product portfolio and geographical reach. For instance, in March 2022, Sanofi S.A., a France based pharmaceutical and healthcare company specialising in the discovery, development, manufacturing, and commercialization of drugs, announced a strategic collaboration with Seagen Inc., a US-based pharmaceutical company specialising in the development and commercialization of novel, powerful monoclonal antibody-based cancer treatments. Under this agreement, the partnership will use Seagen’s and Sanofi’s exclusive monoclonal antibody (mAb) and antibody-drug conjugate (ADC) technologies to design, develop, and market ADCs for up to three cancer targets. Furthermore, Boehringer Ingelheim, a Germany-based research-driven pharmaceutical company, announced a collaboration with MabGenesis, Inc., a Japan-based biopharmaceutical company pioneering in the development of therapeutic monoclonal antibody drugs for the treatment of human diseases. Through this collaboration, Boehringer Ingelheim and MabGenesis discover and develop novel therapeutic monoclonal antibodies for the treatment of various diseases and strategic research and development strategies. Companies in the industry are increasingly realigning their portfolios and pursuing profitable inorganic growth opportunities. Additionally, M&A interest is also being fueled by stronger corporate balance sheets, liquid debt markets, and continued favourable interest rates globally.

Monoclonal Antibodies (MAbS) Market Segment

1) By Source: Murine, Chimeric, Humanized, Human

2) By Application: Anti-Cancer, Immunological, Anti-Infective Monoclonal Antibodies (MAbs), Neuropharmacological, Cardiovascular And Cerebrovascular, Other Applications

3) By End Users: Hospitals, Private Clinics, Research Institute

Monoclonal Antibodies (MAbS) Market Major Players and Strategies

Major players in the monoclonal antibodies (MAbS) market are Johnson & Johnson, Merck, AbbVie, Amgen, GlaxoSmithKline PLC., Norvatis AG, Pfizer Inc., Thermo Fisher Scientific, Eli Lilly and Company, and Bristol-Myers Squibb.

The Monoclonal Antibodies (MAbS) Global Market Report 2023 covers regional data on monoclonal antibodies (MAbS) market size, monoclonal antibodies (MAbS) market trends and drivers, opportunities, strategies, and monoclonal antibodies (MAbS) market competitor analysis. The countries covered in the monoclonal antibodies (MAbS) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Monoclonal antibodies (MABS) refer to laboratory-produced proteins intended to boost your immune system. Treatments for monoclonal antibodies are often administered as IV solutions, frequently in an infusion center. Antibodies are a component of your immune system. To kill them, they seek out the antigens (foreign substances) and adhere to them.

View More Reports Related To The Monoclonal Antibodies (MAbS) Market –

Research Antibodies And Reagents Global Market Report 2023

Biosimilar Monoclonal Antibodies Global Market Report 2023

Conjugated Monoclonal Antibodies Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: